Overview

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Status:
RECRUITING

Trial end date:
2030-12-31

Target enrollment:

Participant gender:

Summary

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cyclophosphamide
fludarabine phosphate
tafasitamab